Entropy Technologies’s BioMarin Pharmaceuticals BMRN Stock Holding History

Entropy Technologies’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-29,572	Closed	-$1.76M	–	910
2025 Q4	$1.76M	Buy	29,572 +6,337	+27%	+$345K	0.1%	273
2025 Q3	$1.26M	Sell	23,235 -5,441	-19%	-$311K	0.09%	278
2025 Q2	$1.58M	Buy	28,676 +18,196	+174%	+$1.07M	0.13%	226
2025 Q1	$741K	Buy	10,480 +2,876	+38%	+$193K	0.07%	334
2024 Q4	$500K	Buy	+7,604	New	+$509K	0.05%	434
2024 Q2	–	Sell	-7,099	Closed	-$620K	–	686
2024 Q1	$620K	Buy	7,099 +4,705	+197%	+$421K	0.07%	388
2023 Q4	$231K	Buy	+2,394	New	+$212K	0.04%	493

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Entropy Technologies's BMRN Position: Q1 2026 in Review

Entropy Technologies sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 29,572 shares — an estimated $1.76M sold.

Entropy Technologies first reported a position in BMRN in Q4 2023 and held it in 7 quarters. The position peaked at $1.76M in Q4 2025. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Entropy Technologies reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Entropy Technologies sold 29,572 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $1.76M.
Entropy Technologies first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 7 quarters.
Entropy Technologies's BioMarin Pharmaceuticals position peaked at $1.76M in Q4 2025.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Entropy Technologies's 13F filing for Q1 2026, filed 14 May 2026.